Why Dry Eyes Are the Perimenopause Symptom Nobody Told You About

Chronic dry eye is two to three times more common in women than men, and the gap is widest in the perimenopausal years. Yet most women who walk into an eye clinic with burning, gritty, light-sensitive eyes have never been told that the cause is hormonal, and that the treatment ladder looks different from the over-the-counter drop aisle. A September 1, 2026 NPR feature highlighted the gap between prevalence and clinical attention, and the 2024 International Menopause Society position statement confirmed that ocular surface disease is a recognized, undertreated component of perimenopause (NPR, 2026). Here is what is happening, why it matters, and what actually helps.

Key Takeaways

• Dry eye disease affects an estimated 16 million Americans and is two to three times more common in women, with prevalence peaking during perimenopause and the first decade after menopause (TFOS DEWS II, 2024 update).
• The mechanism is hormonal: estrogen and androgen receptors on the lacrimal and meibomian glands drive tear production and the lipid layer that keeps tears from evaporating.
• The treatment ladder is no longer "try artificial tears and hope" — prescription anti-inflammatory drops (cyclosporine, lifitegrast), intense pulsed light therapy, and in-office gland expression are evidence-based and widely available.
• Untreated dry eye increases infection risk, blurs vision, and degrades contact lens tolerance; the consequences are not cosmetic.

Why Women Are Different

The ocular surface depends on a stable tear film, which has three layers: a mucin layer that helps the tear film adhere to the eye, a watery aqueous layer that hydrates the cornea, and a thin lipid layer that slows evaporation. Each layer is hormone-responsive.

• Lacrimal gland — produces the aqueous layer. Androgen receptors here are dense, and falling androgen levels (which start to drop earlier than estrogen) reduce aqueous production.
• Meibomian glands — produce the lipid layer. Both androgen and estrogen receptors are present; when either drops, the secreted lipids become more viscous and the glands clog, accelerating tear evaporation.
• Conjunctival goblet cells — produce the mucin layer. Estrogen and progesterone withdrawal reduces mucin secretion, weakening the foundation that the rest of the tear film rests on.

Citation capsule: Estrogen and androgen receptors on the lacrimal gland, meibomian glands, and conjunctival goblet cells all modulate tear film composition, which is why perimenopausal hormonal decline produces ocular surface disease (TFOS DEWS II, 2024 update).

The result is what clinicians call evaporative dry eye combined with aqueous-deficient dry eye, the worst of both. Symptoms include burning, grittiness, foreign-body sensation, light sensitivity, blurred vision that clears with blinking, and paradoxically watery eyes in dry environments (the lacrimal gland overreacts to irritation by producing reflex tears that lack the lipid layer and evaporate almost immediately).

For the broader hormonal picture, see our perimenopause brain fog guide and our perimenopause and cardiovascular risk guide.

The Diagnostic Gap

Most women who present to a primary care visit with dry eye symptoms are told to use over-the-counter artificial tears. The tears help temporarily, but they do not address the underlying inflammation or gland dysfunction, and the symptoms come back within hours. A proper dry eye evaluation involves:

• Symptom questionnaires — the Ocular Surface Disease Index (OSDI) or the Dry Eye Questionnaire (DEQ-5) are validated 5- to 12-item tools that quantify severity and track treatment response.
• Tear osmolarity — a point-of-care test that measures tear film saltiness; values above 308 mOsm/L suggest dry eye and track with severity.
• InflammaDry or MMP-9 testing — detects inflammatory markers on the ocular surface; positive results support the use of anti-inflammatory prescription therapy.
• Meibography — infrared imaging of the meibomian glands; shows gland dropout and clogging.
• Tear break-up time — measures how long the tear film stays stable between blinks; under 10 seconds is abnormal.

Citation capsule: Validated diagnostic tools (OSDI, tear osmolarity, InflammaDry, meibography) are now widely available in optometry and ophthalmology offices and can distinguish evaporative from aqueous-deficient dry eye (TFOS DEWS II).

Most of these are not done in a primary care visit. The practical move is to ask for a referral to an optometrist or ophthalmologist who specializes in ocular surface disease, or to call the office and ask whether they do "dry eye workups."

The 2026 Treatment Ladder

Stepwise treatment is the rule. The 2026 ladder, drawn from the TFOS DEWS II report and the 2024 International Menopause Society position statement:

Step	Intervention	Indication	Notes
1	Lifestyle and environmental	All patients	Humidifier, screen breaks, omega-3 intake, hydration
2	Artificial tears (preservative-free)	Mild symptoms	Avoid preserved drops with frequent use; switch to preservative-free vials
3	Warm compress and lid hygiene	Meibomian gland dysfunction	Warm compress 10 minutes daily, lid massage, hypochlorous acid lid spray
4	Prescription anti-inflammatory drops	Moderate to severe	Cyclosporine 0.05% (Restasis), lifitegrast 5% (Xiidra), or newer perfluoro-octane drops
5	Intense pulsed light (IPL) therapy	Evaporative dry eye from MGD	3-4 sessions 3-4 weeks apart; reduces inflammation and improves gland function
6	Meibomian gland expression	MGD with clogging	In-office manual or device-assisted expression
7	Punctal plugs	Aqueous-deficient	Tiny silicone plugs in the tear drainage ducts to keep tears on the eye longer
8	Autologous serum tears	Severe, refractory	Made from the patient's own blood serum; used when other treatments fail
9	Systemic anti-inflammatory or hormonal evaluation	Perimenopausal women	Confirm whether HRT or topical estrogen/androgen is appropriate

Citation capsule: Intense pulsed light therapy, when added to lid hygiene, can improve meibomian gland function and dry eye symptoms in perimenopausal women with evaporative disease (TFOS DEWS II).

The 2024 International Menopause Society position statement specifically notes that for perimenopausal women, the diagnosis of GSM should be considered alongside ocular surface symptoms, and that systemic hormone therapy may have a role when other dry eye treatments are insufficient.

What Hormone Therapy Actually Does for Dry Eye

The relationship is nuanced. The Women's Health Initiative and other trials of systemic estrogen plus progestin therapy showed a small increase in dry eye symptoms, not a decrease. That counterintuitive result suggested that the timing and type of hormone matters, and that adding estrogen alone to an estrogen-deficient woman is not the answer (International Menopause Society, 2024).

What has more consistent support:

• Topical androgens — androgen eye drops are approved in some countries and in clinical trials in the U.S. They address the dominant hormonal deficit in meibomian gland dysfunction.
• Systemic hormone therapy when appropriate for other indications — for women who are starting systemic HRT for vasomotor symptoms, the dry eye effect varies individually.
• Lifestyle and anti-inflammatory treatments — the most evidence-based interventions for perimenopausal dry eye.

Citation capsule: Systemic estrogen plus progestin therapy is associated with a small increase in dry eye symptoms in some studies, while topical androgen therapy directly targets the underlying meibomian gland deficit (International Menopause Society, 2024).

For women on hormone therapy, see our HRT black-box removal guide for the 2026 update on labels.

What to Do This Week

Three concrete steps for any woman with persistent dry eye symptoms in perimenopause:

1. Switch to preservative-free artificial tears if you are using preserved drops more than three times a day. Preservatives like benzalkonium chloride further damage the ocular surface with chronic use.
2. Add warm compresses and lid hygiene for 10 minutes a day for two weeks. If symptoms improve, the problem was at least partly evaporative and treatable.
3. Ask for a dry eye workup with an eye-care provider who measures tear osmolarity or inflammation markers. Step 4 of the ladder (prescription anti-inflammatory drops) works for most women who reach this point.

Frequently Asked Questions

Can dry eye damage my vision?

Yes. Chronic ocular surface inflammation can scar the cornea and, in severe cases, affect visual acuity. It is not just discomfort.

Are over-the-counter "red eye" drops the same as dry eye drops?

No. Redness-relief drops like Visine constrict blood vessels and can make dry eye worse with prolonged use. Artificial tears, ideally preservative-free, are the appropriate over-the-counter option for lubrication.

Should I take fish oil for dry eye?

Mixed evidence. The DREAM trial in 2018 found no significant benefit of omega-3 supplementation for dry eye. Earlier smaller trials and meta-analyses had been more positive. Omega-3 in normal dietary amounts is reasonable; high-dose supplementation has not held up in rigorous testing.

Is dry eye a permanent part of menopause?

No. Treatment reduces symptoms in most women, and the disease is not progressive in the same way that glaucoma or macular degeneration are. Combination therapy works for most, and refractory cases have options like autologous serum tears and scleral lenses.

Conclusion

Chronic dry eye in perimenopausal women is a hormone-mediated disease with a real evidence-based treatment ladder. The 2026 story is not "this is just dryness, use drops." It is: validate the symptoms with a proper workup, treat the underlying gland dysfunction and inflammation, and escalate to anti-inflammatory prescription therapy or IPL when needed. The over-the-counter shelf is a start, but for the roughly one in three perimenopausal women with clinically significant dry eye, it is rarely the end.

Sources

• Godoy M. Dry eyes are common among women. Here's why you shouldn't ignore it. NPR. September 1, 2026. https://www.npr.org/2026/09/01/nx-s1-5943165-e1/dry-eyes-are-common-among-women-heres-why-you-shouldnt-ignore-it
• Tear Film and Ocular Surface Society. Dry Eye Workshop II (TFOS DEWS II) report. Ocular Surface. 2017; updated 2024. https://www.tfosdewsreport.org
• International Menopause Society. Ocular surface changes in menopause. 2024 position statement. https://www.imsociety.org
• American Academy of Ophthalmology. Dry eye syndrome preferred practice pattern. 2024. https://www.aao.org